$\square$ 

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

nours per response: 0.5	Estimated average burden	
	nours per response:	0.5

STAAB TH	Iress of Reporting F		2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX ]		tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) below)		
(Last)(First)(Middle)4505 EMPEROR BLVD.SUITE 200		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/09/2019		Senior Vice President and CFO		
(Street) DURHAM (City)	NC (State)	27703 (Zip)	<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> </ul>	6. Indiv Line) X	ridual or Joint/Group Fili Form filed by One Re Form filed by More the Person	porting Person	

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		•	,		,					
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	ecurities eneficially wned Following (I) (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock <sup>(1)</sup>	05/09/2019		М		9,750	A	\$5.51	142,426	D	
Common Stock <sup>(1)</sup>	05/09/2019		S		9,750	D	\$7.63 <sup>(2)</sup>	132,676	D	
Common Stock <sup>(1)</sup>	05/13/2019		М		9,750	A	\$5.51	142,426	D	
Common Stock <sup>(1)</sup>	05/13/2019		S		9,750	D	\$7.76 <sup>(3)</sup>	132,676	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(- 37	,		, -		-, -			,										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares										
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.51	05/09/2019		М			9,750	02/27/2018	02/27/2027	Common Stock	9,750	\$0	141,000	D							
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.51	05/13/2019		М			9,750	02/27/2018	02/27/2027	Common Stock	9,750	\$0	131,250	D							

Explanation of Responses:

1. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019.

2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$7.51 to \$7.78. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

3. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$7.65 to \$7.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

<u>/s/ Alane P. Barnes, by power</u>	05/13/2019
<u>of attorney</u>	03/13/2019
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.